Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $137.0 million.

  • Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) rose 976.47% to $137.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $137.0 million, marking a year-over-year increase of 976.47%. This contributed to the annual value of $133.8 million for FY2025, which is 1166.6% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $137.0 million, which was up 976.47% from $133.8 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $139.0 million during Q2 2025, with a 5-year trough of $103.7 million in Q3 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $106.9 million (2023), whereas its average is $115.1 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 114.83% in 2023, then surged by 1622.96% in 2024.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $104.5 million in 2021, then grew by 1.44% to $106.0 million in 2022, then increased by 1.3% to $107.4 million in 2023, then increased by 16.23% to $124.8 million in 2024, then increased by 9.76% to $137.0 million in 2025.
  • Its last three reported values are $137.0 million in Q4 2025, $133.8 million for Q3 2025, and $139.0 million during Q2 2025.